Editorial Advisory Board | Modern RetinaEditorial Advisory Board Ashkan M. Abbey, MD Director of Clinical Research Medical and Surgical Retinal Specialist Texas Retina Associates Dallas, TX ...

Anti-VEGF innovations in retinal disease: From molecules to medicine ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

Diabetic Retinopathy | clinical | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...

New treatment options enhance patient visual outcomes and reduce treatment burdens. The PHOTON study (NCT04429503) evaluated the safety and efficacy of high-dose aflibercept (Eylea; Regeneron ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

A mutation-agnostic gene therapy approach offers new possibilities for patients with advanced retinal disease. Degenerative retinal disease progressively damages the photoreceptors responsible for ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME. This ...